Legend to receive an upfront payment of $350 million, as well as additional development, production performance, regulatory and sales milestone payments Legend and Janssen to co-develop and co-promote CAR-T cell therapy for multiple myeloma Profits and costs to be shared 50/50 worldwide, exclusive Greater China where 70 percent to Legend and 30 percent to Janssen […]
Somerset, NJ (March 9, 2020): — Legend Biotech Corporation today announced that it has confidentially submitted a draft registration statement on Form F-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of American depositary shares, representing its ordinary shares. The number of American depositary shares to be offered […]
Thank you for your interest in learning more about Legend Biotech.
media@legendbiotech.com
You are going to a website that Legend Biotech does not operate and to which Legend Biotech's privacy policy does not apply. Legend Biotech is not responsible for the content, format, maintenance or policies of the website you are about to visit and does not endorse or monitor any content on such website.